Recent Updates
Recently added Catalysts
RPRX Positive Sentiment

Blood Cancer United Announces $7.5 Million Gift From Royalty Pharma to Expand Therapy Acceleration Program

Tuesday, September 15, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Blood Cancer United has received a $7.5 million donation from Royalty Pharma to enhance its Therapy Acceleration Program. This initiative aims to expedite the development of innovative blood cancer treatments through strategic investments and collaboration with biotech firms. The funding marks a new phase for the venture philanthropy program, with returns reinvested to support future therapies.

Market Sentiment Analysis

POSITIVE FACTORS

  • Significant funding of $7.5 million for blood cancer therapies.
  • Collaboration between Blood Cancer United and Royalty Pharma.
  • Focus on accelerating the development of promising therapies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
1.8%
average across 6 past catalysts

Full Press Release Details

Donation marks a new phase for Blood Cancer United's venture philanthropy program, with returns reinvested to support future therapies
NEW YORK, NY and WASHINGTON, Sept. 15, 2026 /PRNewswire/ -- Blood Cancer United and Royalty Pharma today announced a $7.5 million donation from Royalty Pharma to support Blood Cancer United's Therapy Acceleration Program (TAP), a collaborative venture philanthropy initiative designed to accelerate the development of promising blood cancer therapies through strategic equity investments and hands-on collaboration with biotech companies.

Frequently Asked Questions

What is the purpose of the $7.5 million donation?

The donation supports Blood Cancer United's Therapy Acceleration Program to develop blood cancer therapies.

Who made the donation to Blood Cancer United?

The donation was made by Royalty Pharma.

What is the Therapy Acceleration Program?

It is a venture philanthropy initiative aimed at accelerating blood cancer therapy development.

How will the funds be used?

The funds will be reinvested to support future therapies through strategic investments.

ShareAdd on Google
Tags: RPRX Viatris Investor Conferences Healthcare Royalty Pharma Blood Cancer United therapy acceleration blood cancer venture philanthropy
Last updated: Sep 15, 2026

Biotech snapshot

Cash runway
$1209M liquidity · $0M/mo burn
Low dilution risk

Catalyst track record

+53%
best trade around RPRX's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for RPRX.

See every catalyst's timing & PoA →